Gene expression profiles and molecular markers to predict recurrence of Dukes' B colon cancer

Journal of Clinical Oncology

Volumn 22, Issue 9, 2004, Pages 1564-1571

  Wang, Yixin ^a   Jatkoe, Tim ^a   Zhang, Yi ^a   Mutch, Matthew G ^a   Talantov, Dmitri ^a   Jiang, John ^a   McLeod, Howard L ^a   Atkins, David ^a  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RNA; TUMOR MARKER;

ARTICLE; CANCER RECURRENCE; COLON CANCER; DNA MICROARRAY; GENE EXPRESSION; HUMAN; MAJOR CLINICAL STUDY; MARKER GENE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; ADJUVANT CHEMOTHERAPY; ALGORITHM; CANCER STAGING; COLON TUMOR; DISEASE FREE SURVIVAL; EVALUATION; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC MARKER; GENETICS; MALE; METHODOLOGY; MIDDLE AGED; PATHOLOGY; PREDICTION AND FORECASTING; RISK FACTOR; SENSITIVITY AND SPECIFICITY; TUMOR RECURRENCE;

ALGORITHMS; CHEMOTHERAPY, ADJUVANT; COLONIC NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC MARKERS; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RISK FACTORS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 2442684455     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.08.186     Document Type: Article

References (49)

1. Greenlee RT, Hill-Harmon MB, Murray T, et al: Cancer Statistics, 2001. CA Cancer J Clin 51:15-36, 2001
2. Compton CC, Fielding LP, Burgart LJ, et al: Prognostic factors in colorectal cancer: College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 124:979-994, 2000
3. Steinberg SM, Barwick KW, Stablein DM: Importance of tumor pathology and morphology in patients with surgically resected colon cancer: Findings from the Gastrointestinal Tumor Study Group. Cancer 58:1340-1345, 1986
4. Wolters U, Stutzer H, Keller HW, et al: Colorectal cancer: A multivariate analysis of prognostic factors. Eur J Surg Oncol 22:592-597, 1996
5. Guerra A, Borda F, Javier Jimenez F, et al: Multivariate analysis of prognostic factors in resected colorectal cancer: A new prognostic index. Eur J Gastroenterol Hepatol 10:51-58, 1998
6. Saltz LB, Kelsen DP: Adjuvant treatment of colorectal cancer. Annu Rev Med 48:191-202, 1997
7. Moertel CG, Fleming TR, Macdonald JS, et al: Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: A final report. Ann Intern Med 122: 321-326, 1995
8. Wolmark N, Rockette H, Mamounas E, et al: Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes' B and C carcinoma of the colon: Results from National Surgical Adjuvant Breast and Bowel Project C-04. J Clin Oncol 17:3553-3559, 1999
9. International Multicenter Pooled Analysis of B2 Colon Cancer Trials (IMPACT B2) Investigators: Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. J Clin Oncol 17: 1356-1363, 1999
10. Mamounas E, Wieand S, Wolmark N, et al: Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: Results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04). J Clin Oncol 17: 1349-1355, 1999
11. Jass JR: Towards a molecular classification of colorectal cancer. Int J Colorectal Dis 14:194-200, 1999
12. Gennari L, Doci R, Rossetti C: Prognostic factors in colorectal cancer. Hepatogastroenterology 47:310-314, 2000
13. Ratto C, Sofo L, Ippoliti M, et al: Prognostic factors in colorectal cancer: Literature review for clinical application. Dis Colon Rectum 41: 1033-1049, 1998
14. Watanabe T, Wu TT, Catalano PJ, et al: Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N Engl J Med 344:1196-1206, 2001
15. Barratt PL, Seymour MT, Stenning SP, et al: UKCCCR AXIS trial collaborators: Adjuvant X-ray and Fluorouracil Infusion Study-DNA markers predicting benefit from adjuvant fluorouracil in patients with colon cancer: A molecular study. Lancet 360:1381-1391, 2002
16. Noura S, Yamamoto H, Ohnishi T, et al: Comparative detection of lymph node micrometastases of stage II colorectal cancer by reverse transcriptase polymerase chain reaction and immunohistochemistry. J Clin Oncol 20:4232-4241, 2002
17. Hawkins N, Norrie M, Cheong K, et al: CpG island methylation in sporadic colorectal cancers and its relationship to microsatellite instability. Gastroenterology 122:1376-1387, 2002
18. Hailing KC, French AJ, McDonnell SK, et al: Microsatellite instability and 8p allelic imbalance in stage B2 and C colorectal cancers. J Natl Cancer Inst 91:1295-1303, 1999
19. Wang C, van Rijnsoever M, Grieu F. et al: Prognostic significance of microsatellite instability and Ki-ras mutation type in stage II colorectal cancer. Oncology 64:259-265, 2003
20. Gryfe R, Kim H, Hsieh ET, et al: Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N Engl J Med 342:69-77, 2000
21. Witzig TE, Loprinzi CL, Gonchoroff NJ, et al: DNA ploidy and cell kinetic measurements as predictors of recurrence and survival in stages B2 and C colorectal adenocarcinoma. Cancer 68:879-888, 1991
22. Martinez-Lopez E, Abad A, Font A, et al: Allelic loss on chromosome 18q as a prognostic marker in stage II colorectal cancer. Gastroenterology 114:1180-1187, 1998
23. Zhou W, Goodman SN, Galizia G, et al: Counting alleles to predict recurrence of early-stage colorectal cancers. Lancet 359:219-225, 2002
24. Chapman MA, Hardcastle JD, Armitage NC: Five-year prospective study of DNA tumor ploidy and colorectal cancer survival. Cancer 76:383-387, 1995
25. Zhou W, Galizia G, Lieto E, et al: Counting alleles reveals a connection between chromosome 18q loss and vascular invasion. Nat Biotechnol 19:78-81, 2001
26. Ogunbiyi OA, Goodfellow PJ, Herfarth K, et al: Confirmation that chromosome 18q allelic loss in colon cancer is a prognostic indicator. J Clin Oncol 16:427-433, 1998
27. Shibata D, Reale MA, Lavin P, et al: The DCC protein and prognosis in colorectal cancer. N Engl J Med 335:1727-1732, 1996
28. Sun XF, Rutten S, Zhang H, et al: Expression of the deleted in colorectal cancer gene is related to prognosis in DNA diploid and low proliferative colorectal adenocarcinoma. J Clin Oncol 17:1745-1750, 1999
29. McLeod HL, Murray GI: Tumor markers of prognosis in colorectal cancer. Br J Cancer 79: 191-203, 1999
30. Frederiksen CM, Knudsen S, Laurberg S, et al: Classification of Dukes' B and C colorectal cancers using expression arrays. J Cancer Res Clin Oncol 129:263-271, 2003
31. Van't Veer LJ, Dai H, van de Vijver MJ, et al: Gene expression profiling predicts clinical outcome of breast cancer. Nature 415:530-536, 2002
32. Van de Vijver MJ, Yudong DH, Van't Veer LJ, et al: A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347:1999-2009, 2002
33. Beer DG, Kardia SLR, Huang C, et al: Gene expression profiles predict survival of patients with lung adenocarcinoma. Nat Med 8:816-824, 2002
34. Bhattacharjee A, Richards WG, Staunton J, et al: Classification of human lung carcinoma by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci U S A 98:13790-13795, 2001
35. Shipp MA, Ross KN, Tamayo P, et al: Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med 8:68-74, 2002
36. Rosenwald A, Wright G, Chan WC, et al: The use of molecular profiling to predict survival after chemotherapy for diffuse larger B-cell lymphoma. N Engl J Med 346:1937-1947, 2002
37. Lipshutz RJ, Fodor SP, Gingeras TR, et al: High density synthetic oligonucleotide arrays. Nat Genet 21:20-24, 1999
38. Yu T, Robb VA, Singh V, et al: The 4.1/ezrin/radixin/moesin domain of the DAL-1 protein 4.1B tumor suppressor interacts with 14-3-3 proteins. Biochem J 365:783-789, 2002
39. Ohtsubo M, Kai R, Furuno N, et al: Isolation of the active cDNA of the human cell cycle gene involved in the regulation of onset of chromosome condensation. Genes Dev 1:585-593, 1987
40. Ziemer LT, Pennica D, Levine AJ, et al: Identification of a mouse homolog of the human BTEB2 transcription factor as a beta-catenin-independent Wnt-1-responsive gene. Mol Cell Biol 21:562-574, 2001
41. Hakansson L, Adell G, Boeryd B, et al: Infiltration of mononuclear inflammatory cells into primary colorectal carcinomas: An immunohistological analysis. Br J Cancer 75:374-380, 1997
42. Moller P, Momburg F, Koretz K, et al: Influence of major histocompatibility complex class I and II antigens on survival in colorectal carcinoma. Cancer Res 51:729-736, 1991
43. Dabiri GA, Young CL, Rosenbloom J, et al: Molecular cloning of human macrophage capping protein cDNA. J Biol Chem 267:16545-16552, 1992
44. Zhang W, Sloan-Lancaster J, Kitchen J, et al: Influence of major histocompatibility complex class I and II antigens on survival in colorectal carcinoma. Cell 92:83-92, 1998
45. Liefers GJ, Cleton-Jansen AM, van de Velde CJ, et al: Micrometastases and survival in stage II colorectal cancer. N Engl J Med 339:223-228, 1998
46. Feezor RJ, Copeland EM III, Hochwald SN: Significance of micrometastases in colorectal cancer. Ann Surg Oncol 9:944-953, 2002
47. Steinberg SM, Barkin JS, Kaplan RS, et al: Prognostic indicators of colon tumors: The Gastrointestinal Tumor Study Group experience. Cancer 57:1866-1870, 1986
48. Markowitz SD, Dawson DM, Willis J, et al: Focus on colon cancer. Cancer Cell 1:233-236, 2002
49. Caplin S, Cerottini JP, Bosman FT, et al: For patients with Dukes' B (TNM stage II) colorectal carcinoma, examination of six or fewer lymph nodes is related to poor prognosis. Cancer 83:666-672, 1998